# Karuna Therapeutics, Inc.  Share Price Target ‘$322.67’, now 2.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/karuna-therapeutics-inc.share-price-target-322.67-now-2.5-upside-potential/4121145132
- Published: 2024-02-29T12:26:01+00:00
- Author: Charlotte Edwards

**Karuna Therapeutics, Inc.** which can be found using ticker (KRTX) have now 15
confirmed analysts covering the stock with the consensus suggesting a rating of ‘
hold’. The range between the high target price and low target price is between $
330.00 and $260.00 calculating the mean target share price we have $322.67. (at 
the time of writing). Given that the stocks previous close was at $314.89 and the
analysts are correct then there would likely be a percentage uptick in value of 
2.5%. Also worth taking note is the 50 day moving average now sits at $306.35 and
the 200 moving average now moves to $222.47. The market cap for the company is 12.04B.
The stock price is currently at: $315.55 USD

 The potential market cap would be $12,334,917,198 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/
E ratio of -, revenue per share of $0.02 and a -24.71% return on assets.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company
creates and delivers transformative medicines for people living with psychiatric
and neurological conditions. Its pipeline is primarily built on the therapeutic 
potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator
of muscarinic receptors that are located both in the central nervous system (CNS),
and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist,
with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic
receptors in the CNS. The Company is developing KarXT for the treatment of acute
psychosis in adults with schizophrenia, as well as for the treatment of psychosis
in Alzheimer’s disease (AD). The Company is also engaged in developing its investigational
TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and
plan to provide details regarding the expected development of KAR-2618.

Share on: